Dermatology as a field encompasses a vast catalogue of over 3000 diseases, and the diagnoses which dermatologists manage range from the common to the obscure. Often, clinical/pathological correlation is essential in making a specific diagnosis, which can then guide evaluation for extracutaneous involvement and inform treatment decisions. As a field, we have a tendency towards 'splitting', dividing diseases into subtypes, which can sometimes benefit the patient and their care team. For instance, patients with MDA-5 dermatomyositis clearly behave quite differently than patients with Mi-2 dermatomyositis, and we may be honing in on specific antibody patterns more tightly associated with malignancy-associated cases. 1 In other cases, 'splitting' may be more artificial, and confuse rather than informfor instance, the various eponymous types of pigmented purpuric dermatoses or the many numbered types of pityriasis rubra pilaris, which often tell patients and clinicians little about prognosis, evaluation or treatment. Occasionally, 'lumping' diseases together under a common unifying umbrella term can provide more useful information to patients and physicians. Bolognia et al.'s 2 'toxic erythema of chemotherapy: a useful clinical term' remains a sterling example of the benefit of 'lumping,' creating a framework for conceptualizing the spectrum of cytotoxic chemotherapy reactions under one unifying term.The terms palisaded neutrophilic and granulomatous dermatitis (PNGD), interstitial granulomatous dermatitis (IGD) and interstitial granulomatous drug reaction (IGDR) each started with a fairly specific initial case definition, based on histological findings, and a narrow range of clinical findings. Over time, as more reports were published, the distinctions between the entities' clinical and histological features have blurred. Importantly, for patients and their dermatologists, the significance of each of these diagnoses is similar: patients require evaluation for connective tissue disease, inflammatory arthritis or drug triggers, and uncommonly may develop these lesions in the setting of malignancy. The unifying term 'reactive granulomatous dermatitis' (RGD) was proposed by Joe English in our 2015 review of these entities. 3 In this issue of JEADV, Kumar et al. 4 provide additional support for the concept of RGD as an encompassing term for this family of diseases. They reviewed 65 patients from the Mayo